Back to Search
THOMAS PISANSKY, M.D.
M.D.
Radiation Oncology Physician
NPI: 1235118415Individual
Specialties, Licenses & Credentials
Diagnostic Radiology Physician
Radiology — Diagnostic Radiology
Code: 2085R0202X
27366(MN)
Radiation Oncology PhysicianPrimary
Radiology — Radiation Oncology
Code: 2085R0001X
27366(MN)
Research & Publications (20)
High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer.
PMID 19046556·Mayo Clin Proc·2008
6-review
External beam radiotherapy as curative treatment of prostate cancer.
PMID 16007894·Mayo Clin Proc·2005
6-review
Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
PMID 14747040·Urology·2003
6-review
The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma.
PMID 12209743·Cancer·2002
8-other
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
PMID 10687990·J Urol·2000
8-other
Predictive factors in localized prostate cancer: implications for radiotherapy and clinical trial design.
PMID 10875449·Semin Urol Oncol·2000
6-review
Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
PMID 19394158·Int J Radiat Oncol Biol Phys·2010
6-review
Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis.
PMID 19464818·Int J Radiat Oncol Biol Phys·2010
8-other
Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer.
PMID 19464826·Int J Radiat Oncol Biol Phys·2009
8-other
Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
PMID 18947941·Int J Radiat Oncol Biol Phys·2009
4-observational
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
PMID 19349549·J Clin Oncol·2009
3-trial
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
PMID 18672274·Urology·2008
4-observational
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
PMID 17418972·Int J Radiat Oncol Biol Phys·2007
4-observational
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
PMID 17513807·J Clin Oncol·2007
8-other
Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
PMID 17084551·Int J Radiat Oncol Biol Phys·2007
3-trial
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
PMID 17084558·Int J Radiat Oncol Biol Phys·2007
4-observational
Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy.
PMID 16978271·BJU Int·2006
6-review
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
PMID 17141830·Urology·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1235118415
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile